WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317452
CAS#: 118081-34-8 (hydrate)
Description: Ceftibuten dihydrate is the dihydrate form of ceftibuten. It is a semisynthetic, beta-lactamase-stable, third-generation cephalosporin with antibacterial activity. Ceftibuten inactivates penicillin-binding proteins located on the inner membrane of the bacterial cell wall. This results in the weakening of the bacterial cell wall and causes cell lysis.
MedKoo Cat#: 317452
Name: Ceftibuten Dihydrate
CAS#: 118081-34-8 (hydrate)
Chemical Formula: C15H18N4O8S2
Exact Mass:
Molecular Weight: 446.46
Elemental Analysis: C, 40.35; H, 4.06; N, 12.55; O, 28.67; S, 14.36
Ceftibuten Dihydrate purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 200mg may be 2 weeks.
Related CAS #: 97519-39-6 (free) 118081-34-8 (hydrate)
Synonym: Ceftibuten Dihydrate; UNII-62F4443RWP; Seftem; ceftibuten.2H2O; Seftem (TN); Cedax (TN); AC1NQZPM; Ceftibuten (dihydrate); CEFTIBUTEN 2-HYDRATE; Ceftibuten hydrate (JP16); SCHEMBL159144; CHEBI:34618; HY-B0698A; 62F4443RWP; AKOS025149353; AN-6406; HE068843; HE299817; O441; FT-0664440; D02121; A803878; I06-1263
IUPAC/Chemical Name: (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;dihydrate
InChi Key: SSWTVBYDDFPFAF-ODPSPGRDSA-N
InChi Code: InChI=1S/C15H14N4O6S2.2H2O/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19;;/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25);2*1H2/b6-1+;;
SMILES Code: C1C=C(N2C(S1)C(C2=O)NC(=O)C(=CCC(=O)O)C3=CSC(=N3)N)C(=O)O.O.O
The following data is based on the product molecular weight 446.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Kresken M, Körber-Irrgang B, Biedenbach DJ, Batista N, Besard V, Cantón R,
García-Castillo M, Kalka-Moll W, Pascual A, Schwarz R, Van Meensel B,
Wisplinghoff H, Seifert H. Comparative in vitro activity of oral antimicrobial
agents against Enterobacteriaceae from patients with community-acquired urinary
tract infections in three European countries. Clin Microbiol Infect. 2015 Aug 29.
pii: S1198-743X(15)00805-8. doi: 10.1016/j.cmi.2015.08.019. [Epub ahead of print]
PubMed PMID: 26321667.
2: Seki T, Kimura K, Reid ME, Miyazaki A, Banno H, Jin W, Wachino J, Yamada K,
Arakawa Y. High isolation rate of MDR group B streptococci with reduced
penicillin susceptibility in Japan. J Antimicrob Chemother. 2015
Oct;70(10):2725-8. doi: 10.1093/jac/dkv203. Epub 2015 Jul 13. PubMed PMID:
26169560.
3: Kamiya C, Kimura K, Doyama Y, Miyazaki A, Morimoto M, Banno H, Nagano N, Jin
W, Wachino J, Yamada K, Arakawa Y. Ceftibuten-containing agar plate for detecting
group B streptococci with reduced penicillin susceptibility (PRGBS). Diagn
Microbiol Infect Dis. 2015 Aug;82(4):269-73. doi:
10.1016/j.diagmicrobio.2015.04.010. Epub 2015 May 1. PubMed PMID: 25959629.
4: Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Zaffiro A, Caruso C, Quaratino
D. IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and
tolerability of alternative cephalosporins. J Allergy Clin Immunol. 2015
Sep;136(3):685-691.e3. doi: 10.1016/j.jaci.2015.03.012. Epub 2015 Apr 28. PubMed
PMID: 25930196.
5: Sato T, Hara T, Horiyama T, Kanazawa S, Yamaguchi T, Maki H. Mechanism of
resistance and antibacterial susceptibility in extended-spectrum β-lactamase
phenotype Klebsiella pneumoniae and Klebsiella oxytoca isolated between 2000 and
2010 in Japan. J Med Microbiol. 2015 May;64(Pt 5):538-43. doi:
10.1099/jmm.0.000057. Epub 2015 Mar 26. PubMed PMID: 25813819.
6: Tsarev VN, Chuvilkin VI, Akhmedov GD, Chuvilkina EI, Gadzhiev FN, Nikitin IV.
[PCR rationale for use of oral cephalosporins by oral surgery procedures].
Stomatologiia (Mosk). 2014;93(5):43-7. Russian. PubMed PMID: 25588340.
7: Demirel I, Kruse R, Önnberg A, Persson K. Ceftibuten-induced filamentation of
extended spectrum beta lactamase (ESBL)-producing uropathogenic Escherichia coli
alters host cell responses during an in vitro infection. Microb Pathog. 2015
Jan;78:52-62. doi: 10.1016/j.micpath.2014.11.015. Epub 2014 Nov 27. PubMed PMID:
25433242.
8: Nagano N, Nagano Y, Toyama M, Kimura K, Shibayama K, Arakawa Y.
Penicillin-susceptible group B streptococcal clinical isolates with reduced
cephalosporin susceptibility. J Clin Microbiol. 2014 Sep;52(9):3406-10. doi:
10.1128/JCM.01291-14. Epub 2014 Jun 11. PubMed PMID: 24920773; PubMed Central
PMCID: PMC4313170.
9: Nakamura T, Komatsu M, Yamasaki K, Fukuda S, Higuchi T, Ono T, Nishio H,
Sueyoshi N, Kida K, Satoh K, Toda H, Toyokawa M, Nishi I, Sakamoto M, Akagi M,
Mizutani T, Nakai I, Kofuku T, Orita T, Zikimoto T, Natsume S, Wada Y.
Susceptibility of various oral antibacterial agents against extended spectrum
β-lactamase producing Escherichia coli and Klebsiella pneumoniae. J Infect
Chemother. 2014 Jan;20(1):48-51. doi: 10.1016/j.jiac.2013.08.004. Epub 2013 Dec
11. PubMed PMID: 24462425.
10: Keating GM. Fosfomycin trometamol: a review of its use as a single-dose oral
treatment for patients with acute lower urinary tract infections and pregnant
women with asymptomatic bacteriuria. Drugs. 2013 Nov;73(17):1951-66. doi:
10.1007/s40265-013-0143-y. Review. PubMed PMID: 24202878.
11: Chuvilkin VI, Chuvilkina EI, Tsarev VN, Shirokov IuE. [Preventive
antibacterial treatment in oral bone augmentation procedures]. Stomatologiia
(Mosk). 2013;92(3):84-7. Russian. PubMed PMID: 23752848.
12: Liu YL, Wu PS, Tsai LP, Tsai WH. Pediatric round pneumonia. Pediatr Neonatol.
2014 Dec;55(6):491-4. doi: 10.1016/j.pedneo.2013.01.014. Epub 2013 Mar 13. PubMed
PMID: 23597522.
13: Perepanova TS, Kozlov RS, Dekhnich AV, Palagin IS, Shevelev AN, Volkova EM,
Égamberdiev DK. [Choice of antibacterial drugs in urinary infection]. Urologiia.
2012 Mar-Apr;(2):4-8. Russian. PubMed PMID: 22876623.
14: Lo JY, Ho KM, Lo AC. Surveillance of gonococcal antimicrobial susceptibility
resulting in early detection of emerging resistance. J Antimicrob Chemother. 2012
Jun;67(6):1422-6. doi: 10.1093/jac/dks036. Epub 2012 Feb 14. PubMed PMID:
22334602.
15: Tärnberg M, Ostholm-Balkhed A, Monstein HJ, Hällgren A, Hanberger H, Nilsson
LE. In vitro activity of beta-lactam antibiotics against CTX-M-producing
Escherichia coli. Eur J Clin Microbiol Infect Dis. 2011 Aug;30(8):981-7. doi:
10.1007/s10096-011-1183-4. Epub 2011 Feb 6. PubMed PMID: 21298459.
16: Livermore DM, Mushtaq S, Nguyen T, Warner M. Strategies to overcome
extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae. Int J
Antimicrob Agents. 2011 May;37(5):405-9. doi: 10.1016/j.ijantimicag.2010.11.028.
Epub 2011 Jan 26. PubMed PMID: 21276715.
17: Andrews M, Condren M. Once-daily amoxicillin for pharyngitis. J Pediatr
Pharmacol Ther. 2010 Oct;15(4):244-8. PubMed PMID: 22477812; PubMed Central
PMCID: PMC3042262.
18: Zaffanello M, Cataldi L, Franchini M, Fanos V. Evidence-based treatment
limitations prevent any therapeutic recommendation for acute poststreptococcal
glomerulonephritis in children. Med Sci Monit. 2010 Apr;16(4):RA79-84. Review.
PubMed PMID: 20357732.
19: Kimura K, Wachino J, Kurokawa H, Suzuki S, Yamane K, Shibata N, Arakawa Y.
Practical disk diffusion test for detecting group B streptococcus with reduced
penicillin susceptibility. J Clin Microbiol. 2009 Dec;47(12):4154-7. doi:
10.1128/JCM.02063-08. Epub 2009 Oct 7. Erratum in: J Clin Microbiol. 2010
Mar;48(3):1016. PubMed PMID: 19812274; PubMed Central PMCID: PMC2786660.
20: Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended
spectrum cephalosporins. Curr Opin Infect Dis. 2009 Feb;22(1):87-91. doi:
10.1097/QCO.0b013e328320a836. Review. PubMed PMID: 19532086.
